구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Pexa-Vec |
Overview Company | Centre Leon Berard |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Metastatic Tumor; Advanced Tumor |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.. Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a network meta-analysis was conducted. A total of 5948 studie… |
Clinical Safety signal | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.. Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a network meta-analysis was conducted. A total of 5948 studie… |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03071094 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03071094 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Pexa-Vec |
Overview Company | Centre Leon Berard |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Metastatic Tumor; Advanced Tumor |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.. Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a network meta-analysis was conducted. A total of 5948 studie… |
Clinical Safety signal | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.. Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a network meta-analysis was conducted. A total of 5948 studie… |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03071094 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03071094 |
추천 비교
추천 비교